Monitor the case for substantive rulings on patent validity and infringement, which could affect Novo Nordisk's market exclusivity for semaglutide products. The protective order is routine and has no immediate trading implications.
Drugs in focus
NVO drug pipeline →semaglutide
◆ Mixed Named in this court ruling- Impact
- Phase
- Approved - Generic
- Time to market
- Already launched in India (March 2026) and Canada (May 2026), but supply halted until ~October 2026 due to API impurity. US market entry not expected until patent exclusivity ends ~2031-2032.
- Next catalyst
- None dated
What to watchWatch for Dr. Reddy's API remediation progress and the late-October 2026 supply restart timeline. The supply halt halved the FY27 production target from 12M to 6-7M pens and erased ~$678M in market cap. Any update on resolving the impurity issue, regulatory findings, or competitive dynamics (Apotex, USV) could move shares. US market entry (2031-2032 patent expiry) is the long-term prize but too distant to trade on now.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The court entered a stipulated protective order in Novo Nordisk's patent litigation against Mochi Health Corp., governing the handling of confidential information and trade secrets during discovery. This is a routine procedural step that does not resolve any substantive claims or impose any liability.
Court Ruling Details
Key Facts
- Novo Nordisk A/S and Novo Nordisk Inc. are plaintiffs in a patent infringement case against Mochi Health Corp., Mochi Medical CA P.C., and Mochi Medical P.A.
- The case is pending in the Northern District of California, Case No. 5:25-cv-06563-EKL.
- The court entered a stipulated protective order on November 13, 2026, governing the designation and handling of confidential and highly confidential information.
- The protective order includes a prosecution bar restricting involvement in patent prosecution related to semaglutide or its analogs for one year after judgment or settlement.
- No substantive ruling on patent validity, infringement, or damages was made.
Financial Impact
No financial impact; procedural order only.
Risk Factors
- No substantive claims resolved; patent litigation remains pending.
- Future adverse rulings on patent validity or infringement could impact revenue from semaglutide.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-30bf2dbef8-NVO |
Track record
43 reports on NVO
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +23.56% at T+60 after the Jul 28, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $41.89 Now $41.60 −0.69% settles Dec 15
- Nov 13, 20264d ago Court Ruling Neutral 3/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
- Nov 13, 20264d ago Court Ruling Neutral 1/10 Viewing Entry $42.01 Now $41.60 −0.98% settles Dec 15
- Nov 9, 20267d ago 6-K Neutral 2/10 Entry $41.38 Now $41.60 +0.53% settles Dec 8
- Nov 5, 202611d ago Institutional Cluster Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
- Nov 5, 202611d ago 6-K Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
- Nov 4, 202612d ago 6-K Bullish 6/10 Entry $42.18 Now $41.60 −1.38% settles Dec 3
- Nov 3, 202613d ago 6-K Neutral 2/10 Entry $40.19 Now $41.60 +3.51% settles Dec 2
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $39.13 Now $41.60 +6.31% settles Nov 23
- Oct 26, 202622d ago Court Ruling Neutral 4/10 Entry $38.67 Now $41.60 +7.58% settles Nov 24
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers